SML3104

Pazopanib

≥98% (HPLC)

• Sinonimo/i: 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide, 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, GW 786034, GW786034
• Formula empirica (notazione di Hill): C₂₁H₂₃N₇O₂S
• Numero CAS: 444731-52-6
• Peso molecolare: 437.52
• Numero MDL: MFCD11616589
• Codice UNSPSC: 12352200
• NACRES: NA.77

Proprietà

• Livello qualitativo: 100
• Saggio: ≥98% (HPLC)
• Forma fisica: powder
• Colore: white to beige
• Solubilità: DMSO: 2 mg/mL, clear (warmed)
• Temperatura di conservazione: 2-8°C
• Stringa SMILE: CN1N=C2C=C(N(C3=NC(NC4=CC=C(C(S(N)(=O)=O)=C4)C)=NC=C3)C)C=CC2=C1C
• InChI: 1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25); CUIHSIWYWATEQL-UHFFFAOYSA-N

Descrizione

Azioni biochim/fisiol

Pazopanib is an orally active receptor tyrosine kinases inhibitor against VEGFR1/2/3 (IC50 = 10/30/47 nM), PDGFR1/2 (IC50 = 84/71 nM) and c-Kit (IC50 = 74 nM), exhibiting reduced or no potency toward FGFR1/3 (IC50 = 140/130 nM), c-fms (IC50 = 146 nM), and other kinases tested (IC50 from >400 nM to >20 μM). Pazopanib exhibits anti-cancer efficacy in cultures (IC50 from 5 to 15 μg/mL; multiple myeloma migration and survival) and in mice in vivo (30-100 mg/kg/day p.o. against human MM xenografts) via angiogenesis inhibition and apoptosis induction.

Informazioni sulla sicurezza

• Pittogrammi: GHS08,GHS09
• Avvertenze: Danger
• Indicazioni di pericolo: H360FD,H373,H411
• Consigli di prudenza: P202 - P260 - P273 - P280 - P308 + P313 - P391
• Classi di pericolo: Aquatic Chronic 2 - Repr. 1B - STOT RE 2
• Organi bersaglio: Liver
• Codice della classe di stoccaggio: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe di pericolosità dell'acqua (WGK): WGK 3
• Punto d’infiammabilità (°F): Not applicable
• Punto d’infiammabilità (°C): Not applicable